natgillin/translations-raw huggingface dataset:
Patienterne i de 2 prospektive studier blev behandlet med Soliris i 26 uger, og de fleste patienter fortsatte derefter i et langvarigt, ikke-blindet forlængelsesstudie.
Patients in both prospective studies were treated with Soliris for 26 weeks and most patients enrolled into a long-term, open-label extension study.
Patienterne i de fire åbne fase 1- og 2-forsøg blev behandlet med mindst én dosis Erivedge i monoterapi med doser 150 mg.
In four open label phase 1 and 2 clinical trials patients were treated with at least one dose of Erivedge monotherapy at doses  150 mg.
Patienterne i det placebo-kontrollerede studie havde en MMSE-score (Mini-Mental State Examination) på 10-20.
Patients involved in the placebo-controlled study had an MMSE (Mini-Mental State Examination) score of 10–20.
Patienterne i dette studie (n=452) havde lokalt, recidiverende, inoperabelt og/eller metastatisk bløddelssarkom af en ud af to undertyper – leiomyosarkom eller liposarkom.
The patients in this study (n=452) had locally recurrent, inoperable and/or metastatic soft tissue sarcoma of one of two subtypes – leiomyosarcoma or liposarcoma.
Patienterne i disse studier, 108, 111 og C216, havde kompenseret leversygdom, påviseligt HCV-RNA, og lever-histopatologi svarende til kronisk hepatitis C. Med mindre andet angives, blev INCIVO givet i en dosis på 750 mg hver 8. time.
Patients in these studies, 108, 111 and C216, had compensated liver disease, detectable HCV RNA, and liver histopathology consistent with chronic hepatitis C. Unless otherwise indicated, INCIVO was administered at a dosage of 750 mg every
Patienterne i emtricitabin- og tenofovirdisoproxilfumarat-gruppen fik Truvada og efavirenz fra uge 96 til uge 144.
Patients in the emtricitabine and tenofovir disoproxil fumarate group were given Truvada and efavirenz from week 96 to week 144.
Patienterne i fluticasonfuroat/vilanterol- gruppen opnåede en gennemsnitlig ændring i trough-FEV1 (udregnet vha. mindste kvadraters metode) fra baseline på 281 ml, og patienterne i salmeterol/FP-gruppen en ændring på 300 ml (forskellen i justeret gennemsnit på 19 ml (95% konfidensinterval -0,073;0,034) var ikke statistisk significant (p=0,485)).
For trough FEV1 subjects in the fluticasone furoate/vilanterol group achieved a LS mean change from baseline of 281 mL and subjects in salmeterol/FP group a change of 300 mL; (the difference in adjusted mean of 19 mL (95%CI:-0.073, 0.034) was not statistically significant (p=0.485).
Patienterne i fluticasonfuroat/vilanterol- gruppen opnåede en gennemsnitlig ændring i trough-FEV1 (udregnet vha. mindste kvadraters metode) fra baseline på 281 ml, og patienterne i salmeterol/FP-gruppen en ændring på 300 ml (forskellen i justeret gennemsnit på 19 ml (95% konfidensinterval -0,073;0,034) var ikke statistisk significant (p=0,485)).
For trough FEV1 subjects in the fluticasone furoate/vilanterol group achieved a LS mean change from baseline of 281 mL and subjects in the salmeterol/FP group a change of 300 mL; (the difference in adjusted mean of 19 mL (95%CI:-0.073, 0.034) was not statistically significant (p=0.485).
Patienterne i forsøg I, II og III blev testet på forskellige tidspunkter for antistoffer mod adalimumab fra til 12. måned.
Patients in Studies I, II and III were tested at multiple timepoints for antibodies to adalimumab during the 6 to 12 month period.
Patienterne i Gazyvaro plus bendamustin-armen, som ikke havde sygdomsprogression (dvs. patienter med komplet respons, partielt respons eller stabil sygdom) ved slutningen af induktionsperioden, fortsatte med at få Gazyvaro- vedligeholdelsesbehandling én gang hver 2. måned i 2 år eller indtil sygdomsprogression (afhængigt af hvad der opstod først).
Patients in the G+B arm who did not have disease progression (i.e. patients with a complete response (CR), partial response (PR) or stable disease (SD)) at the end of induction continued receiving Gazyvaro maintenance once every two months for two years or until disease progression (whichever occurred first).
Patienterne i hver behandlingsgruppe opretholdt deres optimale dosis i 6 måneder.
Patients in each treatment group were maintained at their optimal dose for 6 months.
Patienterne i kombinationsarmen fik nivolumab 1 mg/kg i.v. over 60 minutter og ipilimumab 3 mg/kg i.v. over
Patients in the combination arm received nivolumab 1 mg/kg over 60 minutes and ipilimumab 3 mg/kg over
Patienterne i kontrolgruppen fik kun RT.
Patients in the control arm received RT only.
Patienterne i laser-kontrolgruppen kunne få yderligere laser-fotokoagulation (kaldet ’erstatningsbehandling med laser’) fra uge 12 med minimumsinterval på 12 uger.
Patients in the laser control group could receive additional laser photocoagulation (called ‘rescue laser treatment’) beginning at week 12 with a minimum interval of 12 weeks.
Patienterne i laser-kontrolgruppen kunne få yderligere laser-fotokoagulation (kaldet ’erstatningsbehandling med laser’) fra uge 12 med minimumsinterval på 12 uger.
Patients in the laser control group could receive additional laser photocoagulation (called ‘rescue laser treatment’) beginning at week 12, with a minimum interval of 12 weeks.
Patienterne i Pom+LD-Dex-armen fik 4 mg pomalidomid oralt på dag 1 til 21 i hver 28-dags cyklus.
Patients in the Pom+LD-Dex arm were administered 4 mg pomalidomide orally on Days 1 to 21 of each 28-day cycle.
Patienterne i Preotactgruppen havde en relativ reduktion i risiko for en ny vertebralfraktur på 61% efter 18 måneders behandling i forhold til patienterne i placebogruppen.
Patients in the Preotact treatment group had a 61 relative risk reduction of a new vertebral fracture at month 18 compared to the patients in the placebo group.
Patienterne i Rd- og Rd18-armene tog lenalidomid 25 mg én gang dagligt på dag 1 til 21 af 28-dages cyklusser, i henhold til protokollens arm.
Patients in the Rd and Rd18 arms took lenalidomide 25 mg once daily on Days 1 to 21 of 28-day cycles according to protocol arm.
Patienterne i reumatoid artrit-studierne I, II og III blev testet på forskellige tidspunkter for anti- adalimumab antistoffer fra 6. til 12. måned.
Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti- adalimumab antibodies during the 6 to 12 month period.
Patienterne i reumatoid artrit-studierne I, II og III blev testet på forskellige tidspunkter for anti- adalimumab antistoffer mod adalimumab fra 6. til 12. måned.
Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti- adalimumab antibodies during the 6 to 12 month period.
Patienterne i studie I randomiseredes til abatacept 2 eller 10 mg/kg eller placebo i 12 måneder.
Study I patients were randomized to receive abatacept 2 or 10 mg/kg or placebo for 12 months.
Patienterne i studie V randomiseredes til samme faste abataceptdosis eller 3 mg/kg infliximab eller placebo i 6 måneder.
Study V patients were randomized to receive this same fixed dose of abatacept or 3 mg/kg infliximab or placebo for 6 months.
Patienterne i studie V randomiseredes til samme faste abataceptdosis eller mg/kg infliximab eller placebo i 6 måneder.
Study V patients were randomized to receive this same fixed dose of abatacept or 3 mg/kg infliximab or placebo for 6 months.
Patienterne i studierne I – V havde en gennemsnitlig Disease Activity Score (DAS28) på 6,5-6,8 ved baseline.
Patients in studies I – V had a mean Disease Activity Score (DAS28) of 6.5–6.8 at baseline.
Patienterne i studiet havde en MMSE (Mini-Mental State Examination) score på 10 – 24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10 – 24.
Patienterne i studiet havde en MMSE (Mini-Mental State Examination) score på 10–24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10 – 24.
Patienterne i studiet havde en MMSE (Mini-Mental State Examination) score på 10–24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10-24.
Patienterne i studiet havde en MMSE (Mini-Mental State Examination) score på 10–24.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10–24.
Patienterne i sub-studiet (n=117) i den åbne forlængelse af studie SC-I fik 125 mg subkutan (s.c.) abatacept administreret ugentligt med den fyldte injektionssprøjte i mindst 4 måneder og blev derefter skiftet til 125 mg abatacept s.c. ugentligt med den fyldte pen i 12 uger.
Patients in the sub-study (n=117) of the open-label extension of study SC-I received 125 mg of subcutaneous (SC) abatacept administered weekly via the pre-filled syringe for at least 4 months, and were then switched to receive 125 mg SC abatacept administered weekly via the pre-filled pen for 12 weeks.
Patienterne i TDM4370g/BO21977, der fik 3,6 mg/kg trastuzumabemtansin intravenøst hver 3. uge, havde en gennemsnitlig maksimal serumkoncentration (Cmax) af trastuzumabemtansin på
Patients in TDM4370g/BO21977 who received 3.6 mg/kg of trastuzumab emtansine intravenously every 3 weeks had a mean maximum serum concentration (Cmax) of trastuzumab emtansine of
Patienterne i undersøgelsen blev enten behandlet med Deltyba eller placebo (virkningsløs behandling) i to måneder som tillægsbehandling til andre behandlinger.
Patients in the study were given Deltyba or placebo (a dummy treatment) for 2 months in addition to their other treatments.
Patienterne i undersøgelsen blev enten behandlet med Opsumit eller placebo (virkningsløs behandling), kombineret med andre midler mod PAH, i gennemsnitligt to år.
Patients in the study received either Opsumit or placebo (a dummy treatment) in addition to other PAH treatments for an average of 2 years.
Patienterne i undersøgelsen fortsatte enten med deres igangværende behandling eller fik Xultophy i stedet for GLP-1- agonisten.
Patients in the study either continued with their current treatment or received Xultophy instead of the GLP-1 agonist.
Patienterne i undersøgelsen havde fremskreden serøs æggestokkræft, som inddrog æggelederne eller bughinden.
Patients in the study had high grade serous ovarian cancers, including fallopian tube or peritoneal.
Patienterne i UNITI-1 havde ikke responderet på eller var intolerante over for tidligere anti-TNF-alfa- terapi.
Patients in UNITI-1 had failed or were intolerant to prior anti-TNFα therapy.
Patienterne i UNITI-2 havde ikke responderet på mindst én konventionel behandling, herunder kortikosteroider eller immunmodulatorer, og var enten anti-TNF-alfa-behandlingsnaive (68,6 %) eller havde tidligere fået, men ikke responderet på, anti-TNF-alfa-terapi (31,4 %).
Patients in UNITI-2 had failed at least one conventional therapy, including corticosteroids or immunomodulators, and were either anti-TNF-α naïve (68.6%) or had previously received but not failed anti-TNFα therapy (31.4%).
Patienterne i UNITI-2 havde ikke responderet på mindst én konventionel behandling, herunder kortikosteroider eller immunmodulatorer, og var enten anti-TNF-alfa-naive (68,6 %) eller havde tidligere fået, men ikke responderet på, anti-TNF-alfa-terapi (31,4 %).
Patients in UNITI-2 had failed at least one conventional therapy, including corticosteroids or immunomodulators, and were either anti-TNF-α naïve (68.6%) or had previously received but not failed anti-TNFα therapy (31.4%).
Patienterne i VcR-CAP-armen fik VELCADE (1,3 mg/m2 på dag 1, 4, 8, 11, hvileperiode dag 12-21), rituximab 375 mg/m2 i.v. på dag 1, cyclophosphamid 750 mg/m2 i.v. på dag 1, doxorubicin 50 mg/m2 i.v. på dag 1 og prednison 100 mg/m2 oralt på dag 1 til og med dag 5 af VELCADE-behandlingscyklussens 21 dage.
Patients in the VcR-CAP treatment arm received VELCADE (1.3 mg/m2; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m2 IV on day 1; cyclophosphamide 750 mg/m2 IV on day 1; doxorubicin 50 mg/m2 IV on day 1; and prednisone 100 mg/m2 orally on day 1 through day 5 of the 21 day VELCADE
Patienterne i VcR-CAP-armen fik VELCADE (1,3 mg/m2 på dag 1, 4, 8, 11, hvileperiode dag 12-21), rituximab 375 mg/m2 i.v. på dag 1, cyclophosphamid 750 mg/m2 i.v. på dag 1, doxorubicin 50 mg/m2 i.v. på dag 1 og prednison 100 mg/m2 oralt på dag 1 til og med dag 5 af VELCADE-behandlingscyklussens 21 dage.
Patients in the VcR-CAP treatment arm received VELCADE (1.3 mg/m2; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m2 IV on day 1; cyclophosphamide 750 mg/m2 IV on day 1; doxorubicin 50 mg/m2 IV on day 1; and prednisone 100 mg/m2 orally on day 1 through day 5 of the 21 day VELCADE treatment cycle.
Patienterne kan fortsætte behandlingen i perioder med reversibel, kemoterapi-induceret suppression af knoglemarven, men de skal monitoreres omhyggeligt for komplikationer relateret til neutropeni i denne periode.
Patients may continue therapy during periods of reversible, chemotherapy-induced myelosuppression butthey should be monitored carefully for complications of neutropenia during this time.
Patienterne kan fortsætte med andre osteoporosebehandlinger efter afslutning af FORSTEO- behandlingen.
Following cessation of FORSTEO therapy, patients may be continued on other osteoporosis therapies.
Patienterne kan få allergiske reaktioner eller hypersensitivitetsreaktioner på MabCampath og på murine antistoffer eller kimære-monoklonale antistoffer.
Patients may have allergic or hypersensitivity reactions to MabCampath and to murine or chimeric monoclonal antibodies.
Patienterne kan give sig selv indsprøjtningerne med Xultophy efter at have fået passende oplæring.
Patients can inject themselves with Xultophy if they have been trained appropriately.
Patienterne kan godt selv give injektionerne med NovoMix, hvis de er behørigt instrueret heri.
Patients can inject themselves with NovoMix once they have been trained appropriately.
Patienterne kan have større risiko for at udvikle trombocytopeni og anæmi på grund af muligheden for at få højere kemoterapidoser (f. eks. de højeste doser i det foreskrevne doseringsskema).
Because of the potential of receiving higher doses of chemotherapy (e.g. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia.
Patienterne kan have øget følsomhed for infektioner, især med indkapslede bakterier.
Patients may have increased susceptibility to infections, especially with encapsulated bacteria.
Patienterne kan ikke afgøre, om de fik Lucentis eller skininjektionen.
The patients cannot tell whether they received Lucentis or the sham procedure.
Patienterne kan modtage andre lægemidler under behandlingen med Humira, såsom kortikosteroider (andre -antiinflammatoriske lægemidler).
Patients may be given other medicines during treatment with Humira, such as corticosteroids (other anti-inflammatory medicines).
Patienterne kan modtage en ny laserlysbestråling 96-120 timer efter administration. .
Patients may receive a second laser light application 96-120 hours after administration.
Patienterne kan normalt kontrolleres tilfredsstillende ved at fastholde den anbefalede startdosis (1- 2 mg/kg/dag).
Patients are usually well-controlled by maintaining the recommended starting dose (1-2 mg/kg/day).
Patienterne kan også få calcium- og vitamin D-tilskud, hvis de ikke får tilstrækkeligt gennem deres kost.
Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet.
Patienterne kan også have behov for at tage calcium- og vitamin D-tilskud, hvis de ikke får tilstrækkeligt gennem deres kost.
Patients may also need to take calcium and vitamin D supplements if they do not have enough from their diet.
Patienterne kan opleve forskellige tegn og symptomer, herunder et lavt antal røde blodlegemer (anæmi), behov for blodtransfusion og infektionsrisiko.
Patients can experience a variety of signs and symptoms including a low red blood cell count (anaemia), the need for a blood transfusion, and a risk of infection.
Patienterne kan selv begynde at foretage injektionen, når har fået tilstrækkelig instruktion heri.
Patients can inject themselves once they have been trained appropriately.
Patienterne kan selv give indsprøjtningerne, hvis de er behørigt instrueret heri.
The patients can inject Avonex themselves if they have been trained appropriately.
Patienterne kan tælles i mere end en række. e ICH=intrakraniel blødning. f Klinisk tydelig blødning forbundet med et fald i hæmoglobin ≥3 g/dl men <5 g/dl.
Patients may be counted in more than one row. e ICH=intracranial haemorrhage. f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL.
Patienterne kan tælles i mere end en række. e ICH=intrakraniel blødning. f Klinisk tydelig blødning, der er forbundet med et fald i hæmoglobin ≥3 g/d,l men <5 g/dl.
Patients may be counted in more than one row. e ICH=intracranial haemorrhage. f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL.
Patienterne kan udvise en uforholdsmæssig vægtøgning.
Patients may display disproportionate weight increase.
Patienterne kan være talt med i mere end en række. dICH=intrakraniel blødning. eKlinisk åbenbar blødning relateret til et fald i hæmoglobin på ≥3 g/dl, men <5 g/dl.
Patients may be counted in more than one row. dICH=intracranial haemorrhage. eClinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but <5 g/dL.
Patienterne kunne behandles medicinsk, fortsætte til koronar bypassoperation (CABG) eller gennemgå perkutan koronar- intervention (PCI).
Patients could be medically managed, proceed to coronary artery bypass graft (CABG), or undergo percutaneous coronary intervention (PCI).
Patienterne kunne kun inkluderes, hvis de havde haft hjerteiskæmi i hvile ( 10 minutter) inden for de sidste 24 timer og havde: enten ST-segmentændringer: ST-depression > 0,5 mm i mindre end 30 minutter eller vedvarende ST-forhøjelse > 0,5 mm, der ikke krævede reperfusionsbehandling eller trombolytiske midler, T-takinversion (> 1 mm) eller forhøjet CK-MB.
Patients could be enrolled only if they had experienced cardiac ischemia at rest ( 10 minutes) within the previous 24 hours and had: either ST-segment changes: ST depression > 0.5 mm of less than 30 minutes or persistent ST elevation > 0.5 mm not requiring reperfusion therapy or thrombolytic agents, T-wave inversion (> 1 mm), or increased CK-MB.
Patienterne led alle af vitamin E-mangel og havde ikke reageret på andre vitamin E- behandlinger, der blev indgivet gennem munden.
The patients all had vitamin E deficiency that was not responding to other vitamin E treatments given by mouth.
Patienterne med vægtøgning på ≥7%, ≥15% og ≥25% af deres baseline kropsvægt ved langvarig eksponering (mindst 48 uger) var meget almindelig (henholdsvis 64,4%, 31,7% og 12,3%).
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Patienterne modtog fortsat deres standardbehandling for SLE under undersøgelserne.
The patients continued to receive their standard treatments for SLE during the studies.
Patienterne må IKKE behandles med porfimer, hvis:
Patients should NOT be treated with porfimer if:
Patienterne må ikke få Zurampic, hvis de har en komplikation som følge af hurtig nedbrydning af kræftceller under kræftbehandling (tumorlysesyndrom) eller den sjældne arvelige sygdom Lesch- Nyhan syndrom, som begge forhøjer blodets indhold af urinsyre.
Patients must not take Zurampic if they suffer from tumour lysis syndrome (a complication due to the rapid breakdown of cancer cells during cancer treatment) or a rare hereditary disease called Lesch- Nyhan syndrome, both of which raise uric acid levels in the blood.
Patienterne må ikke gives yderligere infusioner med Gazyvaro, hvis de oplever:
Patients must not receive further Gazyvaro infusions if they experience:
Patienterne må ikke have været smittet med en HI-virus, der sandsynligvis ikke ville have responderet på et eller flere af de tre aktive stoffer i Atripla, inden de påbegyndte deres første hiv-behandlingskombination.
Patients must not have been infected with HIV that was unlikely to respond to any of the three active substances in Atripla before they started their first HIV treatment combination.
Patienterne må ikke indtage nogen antacider (syreneutraliserende midler), mælkeprodukter eller mineraltilskud i fire timer før eller to timer efter, at de har taget Revolade.
Patients should not take any antacids, dairy products or mineral supplements in the four hours before and in the two hours after taking Revolade.
Patienterne må ikke lægge sig ned før 60 minutter efter indtagelse af Bondronat.
Patients should not lie down for 60 minutes after taking Bondronat.
Patienterne må ikke lægge sig ned før 60 minutter efter indtagelse af Iasibon
Patients should not lie down for 60 minutes after taking Iasibon.
Patienterne må ikke lægge sig ned før 60 minutter efter indtagelse af Ibandronsyre Teva.
Patients should not lie down for 60 minutes after taking Ibandronic Acid Teva.
Patienterne må ikke starte behandling med Airexar Spiromax under en eksacerbation, eller hvis de har signifikant eller akut forværring.
Patients should not be initiated on Aerivio Spiromax during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
Patienterne må ikke tage over fire doser om dagen, og der skal gå mindst fire timer mellem hver smertebehandling.
Patients should not take more than four doses a day and should leave a gap of at least four hours between treating each episode of pain.
Patienterne må ikke tygge, sutte eller knuse tabletterne på grund af risiko for orofaryngal ulceration.
Patients should not chew, suck or crush the tablet because of a potential for oropharyngeal ulceration.
Patienterne må ikke tygge, sutte eller knuse tabletterne på grund af risiko for orofaryngeal ulceration.
Patients should not chew , suck or crush the tablet because of a potential for oropharyngeal ulceration.
Patienterne må ikke tygge, sutte eller knuse tabletterne på grund af risiko for orofaryngeal ulceration.
Patients should not chew, suck or crush the tablet because of a potential for oropharyngeal ulceration.
Patienterne måtte ikke være anfaldsfri i ≥ 21 dage.
Patients could not be seizure-free for 21 days.
Patienterne måtte kun have fået efavirenz/emtricitabin/tenofovirdisoproxil som deres første antiretrovirale program, have været i behandling i mindst tre måneder og udtrykt ønske om at skifte program pga. intolerans over for efavirenz.
Patients had to have previously only received efavirenz/emtricitabine/tenofovir disoproxil as their first antiretroviral regimen for at least three months, and wished to switch regimens due to efavirenz intolerance.
Patienterne og deres partner skal anvende effektiv antikonception under eksponeringen af Defitelio og en uge efter behandlingens ophør.
Effective contraception is required for patients and partners of patients during exposure to Defitelio and for one week subsequent to discontinuation.
Patienterne randomiseredes i forholdet 2:1 til Jakavi og bedste tilgængelige terapi.
Patients were randomised 2:1 to Jakavi versus best available therapy.
Patienterne rådes til ikke at køre bil eller betjene maskiner, medens de tager anagrelid, hvis de oplever svimmelhed.
Patients are advised not to drive or operate machinery while taking anagrelide if dizziness is experienced.
Patienterne skal advares mod at føre motorkøretøj eller betjene farlige maskiner, da der er fare for, at buprenorphin/naloxon kan påvirke deres evne til at udføre sådanne aktiviteter.
Patients should be cautioned about driving or operating hazardous machinery in case buprenorphine/naloxone may affect their ability to engage in such activities.
Patienterne skal advares om muligheden for langvarige bivirkninger, især lysfølsomhed, og om nødvendigheden af at søge lægehjælp, hvis de skulle opstå.
Patients should be warned of the possibility of long term side effects, especially photosensitivity, and the need to seek medical assistance if they arise.
Patienterne skal anbefales at anbringe brugte forbindinger og rensematerialer i en forseglet plastpose, da de kan være kontaminerede, og at kassere posen sammen med husholdningsaffaldet.
Advise patients to place used dressings and cleaning materials in a sealed plastic bag as they may be potentially contaminated, and to dispose of the bag in household waste.